Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissuein vivo and in bone marrow culturesin vitro: implications for the assessment of lymphangiogenesis

• DOI: 10.1002/path.1942
• Publication Date: 2006-02-15T13:16:19Z
• Authors: K Schledzewski; M Falkowski; G Moldenhauer; P Metharom; J Kzhyshkowska; R Ganss; A Demory; B Falkowska-Hansen; H Kurzen; S Ugurel; G Geginat; B Arnold; S Goerdt
• Keywords: Lymphatic Endothelium; Lymphangiogenesis

Lymphangiogenesis is a novel prognostic parameter for several cancers that preferentially quantified by immunohistochemistry of the lymphatic endothelium-specific hyaluronan receptor LYVE-1. Recently, specificity LYVE-1 was challenged serendipitous observations expression in rare tissue macrophages. As receptor-like molecule stabilin-1 shared sinusoidal endothelium and macrophages, thorough analysis performed using macrophage-specific markers vivo vitro. In murine tumour models excisional wound healing, occurred subset CD11b+, F4/80+ macrophages co-expressed stabilin-1. Upon comparison single- double-labelling immunofluorescence, it became apparent LYVE-1+ mimic sprouting collapsed vessels. vitro, induced 25–40% bone marrow-derived upon exposure to B16F1 melanoma-conditioned medium IL-4/dexamethasone. By FACS analysis, 11.5% were LYVE-1+, stabilin-1+ double-positive, while 9.9% stabilin-1− 33.5% LYVE-1−, stabilin-1+. Northern western analyses confirmed mRNA protein light current debate about true endothelial trans-differentiation versus mimicry monocytes/macrophages, non-continuous endothelial-like will require further developmental functional analyses. conclusion, findings imply staining must be supplemented double labelling with macrophage order differentiate clearly between lymphatics tumour-infiltrating This improved approach help clarify significance lymphangiogenesis malignant tumours. Copyright © 2006 Pathological Society Great Britain Ireland. Published John Wiley & Sons, Ltd.